TrialClinical cardiology2016

Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.

Steven E Nissen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.